The biotech company Novavax (NVAX) announced on January 21, 2020, that they are developing a coronavirus vaccine. A share of Novavax was traded for less than $ 10 at that time. NVAX stock closed at $ 202.77 on Friday, March 12, 2021, increasing more than 2082.67% in 12 months.
A new study from Novavax has found that the coronavirus vaccine candidate COVID-19 is almost 100% effective in preventing serious illness and death. The Novavax vaccine was 86.3% effective in preventing infection during the last phase of trials in the UK, during a high prevalence of the new strain of COVID-19, called the “British” strain. Meanwhile, the Novavax vaccine was 96.4% effective in protecting against the original strain of coronavirus. Vaccine experts at Novavax have tested their product with over 15,000 volunteers, 27% over 65 years of age.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The South African randomized trial of Novavax’s vaccine identified a more dangerous strain, COVID-19. Overall, 55.4% efficacy of the vaccine was reported among 2,665 HIV-negative adults. There was a vaccination efficacy of 48.6% among 240 medically stable HIV-positive adults.
Filip Dubovsky, Chief Medical Officer of Novavax (NVAX), also explained that the vaccine was well-tolerated, and the risk of serious adverse effects was low.The US government previously provided $1.6 billion to Novavax to assess its vaccine and provide 100 million doses. There is no deadline yet announced by the company for filing applications for approval by the FDA, the US Food and Drug Administration.
Novavax plans to apply for permission to sell its vaccine products in the UK early in the second quarter of 2021, Dubovsky stated in an interview with Reuters. If the US regulators decide that there are enough UK data to justify Novavax for use in the US as soon as May, he said, the vaccine may be approved there by the end of the year.
Researchers in the United States and Mexico expect to report the results of a prospective study of the Novavax vaccine by the end of April. This would suggest that Novavax will not be available until July in the United States if the FDA expects this data.Executives at Novavax previously stated that the vaccine plants would be fully operational by April. At Indian Serum Institute and eight other manufacturing sites, Novavax plans to manufacture its vaccines.
The CEO of Novavax, Stanley Erk, told Reuters in an interview that he expects his company to have tens of millions of doses on hand when the FDA approves the vaccine and available for shipment to the United States.
Vaccine manufacturers conduct additional efficacy trials of their vaccines as health authorities register new strains of COVID-19. A recent study indicates that COVID-19 vaccination will increase vaccine producers’ profits if it is annual vaccination. It appears the future of Novavax (NVAX) looks bright.